Our goal is to be the leading biopharmaceutical company developing and marketing therapies that restore function and improve the lives of people with neurological disorders.

Acorda’s R&D efforts are designed to:

  • Develop CVT-301 as a potential treatment for OFF periods in people with Parkinson’s disease
  • Determine if dalfampridine is a therapeutic option for people with post-stroke walking difficulty
  • Advance CVT-427 as a potential acute treatment for migraine
  • Advance clinical development of rHIgM22, a remyelinating antibody, as a potential treatment for people with MS
Click on a compound in development for more information.
Therapy Indication Phase 1 Phase 2 Phase 3
CVT-301
Parkinson's Disease
 
 
 
TOZADENANT (SYN115)*
Parkinson's Disease
 
 
 
DALFAMPRIDINE
Chronic Post-Stroke Walking Difficulty
 
 
 
SYN120*
Parkinson's Disease
 
 
 
BTT1023*
Primary Sclerosing Cholangitis (PSC)
 
 
 
CVT-427
Migraine
 
 
 
rHlgM22
MS
 
 
 
* pending completion of Biotie Therapies acquisition